That means having your capital tied up in in-transit drugs for two or three months. The cost of that may outweigh the savings from automation.
You also lose the ability to react quickly to market demand.
That approach might be suitable for established industries, but probably not for innovative, disruptive players in a winner-takes-all market like drug cartels.